Skip to content
Publicly Available Published by De Gruyter March 6, 2021

Assessment of the infection dynamics and the disease burden of COVID-19 in Germany

Einschätzung von Infektionsdynamik und Krankheitslast von COVID-19 in Deutschland
  • Berit Lange EMAIL logo
From the journal Public Health Forum

Abstract

The last months of the COVID-19 pandemic have shown that implementing informative indicators for infection dynamics, assessing direct and indirect burden of disease and communicating uncertainties of predictions clearly to stakeholders and the public are crucial elements in the pandemic response. To achieve these aims, coordination within the scientific community is crucial to avoid duplication of work and ensure rapid availability of needed models, estimations, and epidemiological studies.

Zusammenfassung

Die letzten Monate der COVID-19-Pandemie haben gezeigt, dass die Implementierung informativer Indikatoren für die Infektionsdynamik, die Bewertung der direkten und indirekten Krankheitslast und die eindeutige Kommunikation von Unsicherheiten in Bezug auf Vorhersagen an die Interessengruppen und die Öffentlichkeit entscheidende Elemente der Pandemie-Reaktion sind. Um diese Ziele zu erreichen, ist die Koordinierung innerhalb der wissenschaftlichen Gemeinschaft von entscheidender Bedeutung, um Duplizierung von wissenschaftlicher Arbeit zu vermeiden und die rasche Verfügbarkeit der erforderlichen Modelle, Schätzungen und epidemiologischen Studien sicherzustellen.

Using available and building future indicators to assess infection dynamics

One of the major contributions public health can make during a pandemic is the quantitative prediction and timely measurement of infection dynamics and disease burden and the establishment of indicators to this end [1].

Numerous informative indicators of infection dynamics and disease burden are available and were built up during the pandemic in Germany. These include testing frequency and number of positive tests over number of tests performed, how high the positivity risk of these tests is [2], how the reproductive number is developing [3], [4], how many ICU beds are available [5], how many people are currently suffering from respiratory symptoms (AGI), which viruses cause respiratory infections [6] and whether there was excess mortality 4-8 weeks ago [7].

These indicators need have been supplemented by continuous population-based especially seroprevalence studies, indicating low seroprevalences mostly and an expected to observed ratio of 2–8 in Germany as well as infection fatality estimates of 0.5–1.5% [8], [9]. Another potential useful indicator is the expansion of the already existing sentinel surveillance. The number of samples received currently is rather low and an expansion would lead to more stable and detailed results than current notification systems with changing test strategies can provide [6]. A rather novel method – although well-known from other infectious diseases – would be monitoring viral loads in wastewater as an indicator of otherwise unnoticed outbreaks for example in younger population groups [10]. And while we now have a fairly good overview of the utilization of clinical facilities via both the German Society for Intensive Care Medicine (DIVI) and the AKTIN-register (Verbesserung der Versorgungsforschung in der Akutmedizin in Deutschland durch den Aufbau eines Nationalen Notaufnahmeregisters) data [5], we do not know the same for the utilization of public health agencies capacities. Developing similar indicators for health authority capacity would be essential. For that, regional and superregional reporting of indicators such as the number of positive contacts per index case found could be implemented. Excess mortality is another indicator that could be further developed and used. In Germany, the Federal Statistical Office very quickly presented figures on mortality this year [7], and several analyses show that the excess mortality in Germany was low, whereas in other countries, more severely affected by the epidemic during February to July, it was high [11]. What is not possible currently – but important in the future – is to assess cause specific excess mortality. This is due to a lack of time sensitive data on causes of death in most countries. Assessing cause-specific excess mortality would allow to assess direct and indirect regional effects of the pandemic more clearly and in (nearly) real-time.

Including direct and indirect components of disease burden in estimations

The disease burden during a pandemic – whether expressed as mortality, years of life lost or frequency of disease – is ultimately composed of direct and indirect burden of disease (Figure 1) caused both by the pandemic and measures against the pandemic.

Figure 1: Disease burden during the SARS-CoV-2 pandemic (Own illustration).
Figure 1:

Disease burden during the SARS-CoV-2 pandemic (Own illustration).

Disease burden directly caused by SARS-CoV-2 is composed of patients who die from COVID-19, fall ill, or have long-term consequences. The most important variable to influence disease burden of persons infected with SARS-CoV-2 is age. This means that crude case fatality estimates depends fundamentally on the population – in particular age – structure of infected persons, the varying degree of under-reporting of both cases and deaths, a time lag between reporting and death, and the capacity of the health care system in the country treating the disease [12]. While most evidence agrees that advancing age is the single most important risk factor for a severe course of COVID-19, the role of age as an effect modifier of the association of other risk factors such as predisposing conditions and severity of disease is not yet clear [13]. This interaction is important to consider in the design of future non-pharmaceutical strategies as well as vaccination strategies.

Indirect disease burden includes health effects of both the pandemic and the measures taken against the pandemic. These include COVID and non-COVID patients not being treated properly due to health care systems being overburdened [14] and additional burden of disease arises due to underuse of the health care system as patients with chronic conditions no longer want to or are unable to access health care [15]. Furthermore, economic consequences of the pandemic as well as pandemic measures also have health consequences. Positive indirect effects on disease burden of those conditions associated with air pollution [16] and infectious diseases with similar transmission pathways to SARS-CoV-2 such as influenza [17] have been reported.

At the beginning of the pandemic there was little to no evidence for any of the indirect effects of the pandemic. This has now changed and current pandemic measures are aiming at mitigating any of the adverse indirect effects by considering the available evidence [18].

Towards even further coordinated networks of scientists

In March, first simple SIR models were built for the city of Brunswick (Figure 2) and then more sophisticated infectious disease modelling was implemented [3]. In other cities of Germany similar models were created [19] and similarly found that, given the assumed parameters, it was quite possible that intensive care capacities would be exceeded within a few weeks, accompanied by high mortality rates. International quantitative modelling confirmed this and clearly showed that simple containment, without strong measures, was unlikely [20].

Figure 2: The initial “good case” scenario calculated with parameters available in March 2020 and informing ranges of potentially needed hospital beds in Brunswick, Germany based on a very simple SIR model on 15.03.20 (personal archive): Rt initially 2.4, after 4 weeks reduction to 0.9 (Own illustration).
Figure 2:

The initial “good case” scenario calculated with parameters available in March 2020 and informing ranges of potentially needed hospital beds in Brunswick, Germany based on a very simple SIR model on 15.03.20 (personal archive): Rt initially 2.4, after 4 weeks reduction to 0.9 (Own illustration).

So, interestingly, in many cities and regions over Germany similar quick and rapid simulation studies were built up on remarkably similar issues to give rapid assessments. While all individual local models were important, quick, and efficient coordination might have helped early on to integrate the simulation studies available more efficiently with the most important questions infectious disease epidemiologist, official stakeholders and the public were asking. Similarly, it would have been important to integrate the – simultaneously ongoing – evidence synthesis efforts into the modelling platforms and for both to inform each other early on. Several coordination initiatives like this were quickly built up in March, including one led by dgepi (https://www.gmds.de/fileadmin/user_upload/aktuelles-termine/200325_RKI.pdf). However, ideally of course these would have existed in advance and would have provided data from January onwards [21].

Declaring aims and uncertainties in predicting infection dynamics

Simulation studies at this point in time are a representation of the extremes and scenarios more than a detailed forecast of what will happen. It is therefore particularly important at this point in time to explain the usefulness and – non-usefulness of these models very well to political stakeholders and the public and follow simple communication guidelines to this end [22].

Forecasts in the future might consider including parameters such as seroprevalence and thus possible unreported cases, syndrome surveillance, mobility data and possibly even sewage data at the regional level. Forecasts should also aim at providing age specific estimates for COVID-19 where age specificity of exposure, infection, symptomatic and severe course of disease is of paramount importance. Contact structures and contact fields of the population might help if the current contact surveys and matrices are available. Even if developing forecasts to this level however, uncertainties will always persist in any forecast predicting infection dynamics for the next few weeks. Research groups generating these forecasts should consider to communicate aims, limits, and uncertainties carefully, clearly, and transparently, as well as towards stakeholders and towards the public.

Ideally, future forecasts include age-specific estimations and expected indirect as well as direct disease burden based on expected infection dynamics and known consequences of measures to inform regional and superregional pandemic management.

Conclusion

In conclusion, implementing indicators for the utilization and capacity of the public health agencies as well as real time cause-specific excess mortality estimates are essential to implement and coordination within the scientific community is crucial to avoid duplication of work and ensure rapid availability of needed models, estimations, and epidemiological studies. Future prediction models will benefit from including age-specific estimates, known contact structures of the population and measures of direct and indirect burden of disease to inform regional and supraregional pandemic management.


Corresponding author: Berit Lange, MD, MSc, Helmholtz Centre of Infection Research, Department of Epidemiologie, Innhoffenstr. 7, 38124 Braunschweig; and Deutsches Zentrum ruf Infektionsforschung

  1. Author Declaration

  2. The author is responsible for the entire content of this article. Funding: This work was supported by intramural funds from the HZI; from public sources, namely the Federal Ministry of Education and Research and the Helmholtz Society; and through the European Union’s Horizon 2020 research and innovation program [grant number 101003480]. Conflict of interest: The author declares that there is no economic or personal conflict of interest. Ethical statement: No primary data were collected from humans or animals for the research.

  3. Autorenerklärung

  4. Die Autorin trägt Verantwortung für den gesamten Inhalt dieses Artikels. Finanzierung: Diese Arbeit wurde durch intramurale Mittel des HZI unterstützt; aus öffentlichen Quellen, nämlich dem Bundesministerium für Bildung und Forschung und der Helmholtz Gesellschaft; und durch das Forschungs- und Innovationsprogramm Horizont 2020 der Europäischen Union [Bewilligungsnummer 101003480]. Interessenkonflikt: Die Autorin erklärt, dass kein wirtschaftlicher oder persönlicher Interessenkonflikt vorliegt. Ethisches Statement: Für die Forschungsarbeit wurden weder von Menschen noch von Tieren Primärdaten erhoben.

References

1. Gianicolo E, Riccetti N, Blettner M, Karch A. Epidemiologische Maßzahlen im Rahmen der COVID-19-Pandemie. Dtsch Arztebl Int 2020;117:336–42.Search in Google Scholar

2. Staat D SD, Seifried J, Böttcher S, Albrecht S, Willrich N, Zacher B, et al. Erfassung der SARS-CoV-2-Testzahlen in Deutschland (Stand 4.11.2020). Epid Bull 2020;45:16–20.Search in Google Scholar

3. Khailaie S, Mitra T, Bandyopadhyay A, Schips M, Mascheroni P, Vanella P, et al. Development of the reproduction number from coronavirus SARS-CoV-2 case data in Germany and implications for political measures. medRxiv. 2020:2020.04.04.20053637.10.1186/s12916-020-01884-4Search in Google Scholar PubMed PubMed Central

4. an der Heiden M HO. Schätzung der aktuellen Entwicklung der SARS-CoV-2-Epidemie in Deutschland – Nowcasting. Epid Bull 2020;2020;17:10–16.Search in Google Scholar

5. DIVI. Anzahl gemeldeter intensivmedizinisch behandelter COVID-19-Fälle an Anzahl belegter Intensivbetten (*d). 2020.Search in Google Scholar

6. Institut RK. Arbeitsgemeinschaft Influenza 2020. Available from: https://influenza.rki.de/Diagrams.aspx?agiRegion=0.Search in Google Scholar

7. Bundesamt S. Sterbefallzahlen und Übersterblichkeit 2020. Available from: https://www.destatis.de/DE/Themen/Querschnitt/Corona/Gesellschaft/bevoelkerung-sterbefaelle.html.Search in Google Scholar

8. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill. 2020;25.10.2807/1560-7917.ES.2020.25.28.2001285Search in Google Scholar PubMed PubMed Central

9. Santos-Hovener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Euro Surveill 2020;25.10.2807/1560-7917.ES.2020.25.47.2001752Search in Google Scholar PubMed PubMed Central

10. Westhaus S, Weber FA, Schiwy S, Linnemann V, Brinkmann M, Widera M, et al. Detection of SARS-CoV-2 in raw and treated wastewater in Germany – Suitability for COVID-19 surveillance and potential transmission risks. Sci Total Environ 2021;751:141750.10.1016/j.scitotenv.2020.141750Search in Google Scholar PubMed PubMed Central

11. Vanella P, Basellini U, Lange B. Assessing Excess Mortality in Times of Pandemics Based on Principal Component Analysis of Weekly Mortality Data – The Case of COVID-19. ArXiv preprint arXiv:201005850. 2020.10.1186/s41118-021-00123-9Search in Google Scholar PubMed PubMed Central

12. Patrizio V, Christian W, Anja H, Gérard K, Annika M, Sarah W, et al. The Role of Age Distribution, Time Lag Between Reporting and Death and Healthcare System Capacity in Case Fatality Estimates of COVID-19. Res Square. 2020.Search in Google Scholar

13. Fernandez Villalobos NV, Ott JJ, Klett-Tammen CJ, Bockey A, Vanella P, Krause G, et al. Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis. medRxiv. 2020:2020.07.30.20165050.10.1101/2020.07.30.20165050Search in Google Scholar

14. Fagiuoli S, Lorini FL, Remuzzi G, Covid-19 Bergamo Hospital Crisis U. Adaptations and Lessons in the Province of Bergamo. N Engl J Med 2020;382:e71.10.1056/NEJMc2011599Search in Google Scholar PubMed PubMed Central

15. Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med 2020;383:691–3.10.1056/NEJMc2015630Search in Google Scholar PubMed

16. Chen K, Wang M, Huang C, Kinney PL, Anastas PT. Air pollution reduction and mortality benefit during the COVID-19 outbreak in China. Lancet Planet Health 2020;4:e210–e2.10.1016/S2542-5196(20)30107-8Search in Google Scholar PubMed PubMed Central

17. Fricke L, Gloeckner S, Dreier M, Lange B. Impact of non-pharmaceutical interventions targeted at COVID-19 pandemic on influenza burden – a systematic review. J Infect 2020;in press.10.1016/j.jinf.2020.11.039Search in Google Scholar PubMed PubMed Central

18. dgepi. Empfehlungen für eine wirksame, verträgliche und nachhaltige Strategie der Pandemiekontrolle im kommenden Winter und darüber hinaus. dgepi; 2020.Search in Google Scholar

19. Koeppel L, Gottschalk C, Welker A, Knorr B, Denkinger CM. Prediction of local COVID-19 spread in Heidelberg. F1000Res 2020;9:232.10.12688/f1000research.23034.1Search in Google Scholar PubMed PubMed Central

20. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020;584:257–61.10.1038/s41586-020-2405-7Search in Google Scholar PubMed

21. Morse SS, Mazet JAK, Woolhouse M, Parrish CR, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. The Lancet 2012;380:1956–65.10.1016/S0140-6736(12)61684-5Search in Google Scholar PubMed PubMed Central

22. Karamouzian M, Johnson C, Kerr T. Public health messaging and harm reduction in the time of COVID-19. Lancet Psychiat 2020;7:390–1.10.1016/S2215-0366(20)30144-9Search in Google Scholar PubMed PubMed Central

Online erschienen: 2021-03-06
Erschienen im Druck: 2021-03-26

©2021 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.5.2024 from https://www.degruyter.com/document/doi/10.1515/pubhef-2020-0122/html
Scroll to top button